STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

Revolution Medicines director sells 56K shares

A Revolution Medicines director’s revocable trust sold 56,000 RVMD shares under a pre-arranged Rule 10b5-1 trading plan while the director continues to hold restricted stock units.

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) director Lorence H. Kim reported the indirect sale of a total of 56,000 shares of Common Stock on August 31, 2026 through the Lorence Kim Revocable Trust in multiple open‑market transactions at prices around $200–$206 per share. The filing also shows 1,191 restricted stock units held directly and states that these sales were made under a Rule 10b5-1 trading plan adopted by the trust on June 1, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Kim Lorence H.
Role Director
Sold 56,000 shs ($11.38M)
Type Security Shares Price Value
Sale Common Stock F2, F3 300 $200.56 $60K
Sale Common Stock F2, F4, F3 6,597 $201.4729 $1.33M
Sale Common Stock F2, F5, F3 12,919 $202.4819 $2.62M
Sale Common Stock F2, F6, F3 26,160 $203.5483 $5.32M
Sale Common Stock F2, F7, F3 7,271 $204.3501 $1.49M
Sale Common Stock F2, F8, F3 2,128 $205.1879 $437K
Sale Common Stock F2, F9, F3 625 $206.154 $129K
holding Common Stock F1 -- -- --
Holdings After Transaction: Common Stock — 17,090 shares (Indirect, Trust); Common Stock — 1,191 shares (Direct)
Footnotes (9)
  1. F1. Includes 1,191 restricted stock units.
  2. F2. Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
  3. F3. Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13.
  4. F4. The transaction was executed in multiple trades at prices ranging from $201.00 to $201.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. F5. The transaction was executed in multiple trades at prices ranging from $202.00 to $202.9956, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  6. F6. The transaction was executed in multiple trades at prices ranging from $203.0055 to $203.9968, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  7. F7. The transaction was executed in multiple trades at prices ranging from $204.00 to $204.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  8. F8. The transaction was executed in multiple trades at prices ranging from $205.00 to $205.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  9. F9. The transaction was executed in multiple trades at prices ranging from $206.02 to $206.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Shares sold 56,000 shares Total Common Stock sold indirectly on August 31, 2026 via the trust
Sample sale price $201.4729 per share Weighted average price for 6,597 shares sold on August 31, 2026
Largest reported block 26,160 shares at $203.5483 per share Indirect sale by the trust on August 31, 2026
Price range (example trade) $201.00–$201.99 per share One transaction executed in multiple trades within this range, reported as a weighted average
Trust holdings before sale 73,090 shares Shares held by the Lorence Kim Revocable Trust immediately prior to the reported transactions
Direct restricted stock units 1,191 RSUs Restricted stock units held directly by the reporting person as of August 31, 2026
Transfer to trust 23,090 shares Shares transferred to the trust in August 2025 as a change in form of beneficial ownership
10b5-1 plan adoption date June 1, 2026 Date the Lorence Kim Revocable Trust adopted the Rule 10b5-1 trading plan
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 1,191 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price."
pecuniary interest financial
"without a change in the Reporting Person's pecuniary interest and was exempt"
Rule 16a-13 regulatory
"was exempt pursuant to Rule 16a-13."

FAQ

What did the RVMD director report in this Form 4?
The director reported that the Lorence Kim Revocable Trust sold 56,000 shares of Revolution Medicines Common Stock on August 31, 2026 in multiple open‑market transactions, while the director continues to hold 1,191 restricted stock units directly.

At what prices were the 56,000 RVMD shares sold?
The reported sales occurred at per‑share prices generally around $200–$206. For example, trades included 6,597 shares at $201.4729 and 26,160 shares at $203.5483, with several blocks executed over specified price ranges and reported using weighted average sale prices.

Were the RVMD share sales made under a Rule 10b5-1 plan?
Yes. A footnote states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026, and the filing’s Rule 10b5-1 checkbox is affirmed.

Who actually held the RVMD shares that were sold?
The sold shares were held by the Lorence Kim Revocable Trust. A footnote explains that the trust held 73,090 shares immediately before these transactions, consisting of shares acquired in July 2022 and shares transferred to the trust in August 2025.

What RVMD equity does the director hold directly after these transactions?
A holding entry reports that the director directly holds 1,191 restricted stock units of Revolution Medicines. A footnote clarifies that this figure represents restricted stock units included in the reported direct holding.

How many RVMD shares were previously transferred into the trust?
A footnote states that, of the 73,090 shares held by the trust immediately before the reported sales, 23,090 shares were transferred by the reporting person to the trust in August 2025 as a change in the form of beneficial ownership exempt under Rule 16a-13.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kim Lorence H.
(Last)(First)(Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock1,191(1)D
Common Stock08/31/2026S(2)300D$200.5672,790ITrust(3)
Common Stock08/31/2026S(2)6,597D$201.4729(4)66,193ITrust(3)
Common Stock08/31/2026S(2)12,919D$202.4819(5)53,274ITrust(3)
Common Stock08/31/2026S(2)26,160D$203.5483(6)27,114ITrust(3)
Common Stock08/31/2026S(2)7,271D$204.3501(7)19,843ITrust(3)
Common Stock08/31/2026S(2)2,128D$205.1879(8)17,715ITrust(3)
Common Stock08/31/2026S(2)625D$206.154(9)17,090ITrust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes 1,191 restricted stock units.
2. Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
3. Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13.
4. The transaction was executed in multiple trades at prices ranging from $201.00 to $201.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. The transaction was executed in multiple trades at prices ranging from $202.00 to $202.9956, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6. The transaction was executed in multiple trades at prices ranging from $203.0055 to $203.9968, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
7. The transaction was executed in multiple trades at prices ranging from $204.00 to $204.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
8. The transaction was executed in multiple trades at prices ranging from $205.00 to $205.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
9. The transaction was executed in multiple trades at prices ranging from $206.02 to $206.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Jack Anders, as Attorney-in-fact for Lorence H. Kim09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR